The genetics testing company has managed to attract a range of corporate investors, partly through its research activities, and international expansion looks to be on the horizon.

The $115m series E round closed by US-based personal genetics service provider 23andme last week at a $1.1bn valuation, which made it the sector’s first unicorn, showed the potential for companies offering similar services.

The round was led by Fidelity Management & Research, and also featured genetic research company Illumina, Google Ventures and WuXi Healthcare Ventures, respective corporate venturing subsidiaries of internet technology provider Alphabet and pharmaceutical firm WuXi PharmaTech, Casdin Capital, Xfund, New Enterprise Associates and MPM Capital.

…